[go: up one dir, main page]

NI201700137A - Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue - Google Patents

Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue

Info

Publication number
NI201700137A
NI201700137A NI201700137A NI201700137A NI201700137A NI 201700137 A NI201700137 A NI 201700137A NI 201700137 A NI201700137 A NI 201700137A NI 201700137 A NI201700137 A NI 201700137A NI 201700137 A NI201700137 A NI 201700137A
Authority
NI
Nicaragua
Prior art keywords
dengue viral
mono
compounds
disstituted
inhibitors
Prior art date
Application number
NI201700137A
Other languages
English (en)
Inventor
Rudolf Romanie Kesteleyn Bart
Bonfanti Jean-François
Hugo Maria Jonckers Tim
Jean-Marie Bernard Raboisson Pierre
Alice Marie-Eve Bardiot Dorothée
Didier M Marchand Arnaud
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of NI201700137A publication Critical patent/NI201700137A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de indol mono o dissustituidos, a métodos para prevenir o tratar infecciones virales por dengue usando dichos compuestos y también se refiere a dichos compuestos para uso como medicamento, más preferiblemente para uso como una medicina para tratar o prevenir infecciones virales por dengue. La presente invención se refiere adicionalmente a composiciones farmacéuticas o preparaciones de combinación de los compuestos, a las composiciones o preparaciones para su uso como un medicamento, más preferiblemente para la prevención o tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
NI201700137A 2015-05-08 2017-11-07 Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue NI201700137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
NI201700137A true NI201700137A (es) 2019-05-07

Family

ID=56026812

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700137A NI201700137A (es) 2015-05-08 2017-11-07 Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue

Country Status (39)

Country Link
US (5) US10696632B2 (es)
EP (2) EP3896072B1 (es)
JP (4) JP6752821B2 (es)
KR (2) KR102610491B1 (es)
CN (3) CN107873022B (es)
AU (2) AU2016259677B2 (es)
BR (1) BR112017023904A2 (es)
CA (1) CA2981845C (es)
CL (1) CL2017002817A1 (es)
CO (1) CO2017012381A2 (es)
CR (2) CR20200152A (es)
CY (1) CY1124548T1 (es)
DK (1) DK3294738T3 (es)
EA (1) EA034978B1 (es)
EC (2) ECSP17073878A (es)
ES (2) ES2941674T3 (es)
GT (1) GT201700234A (es)
HR (1) HRP20210675T1 (es)
HU (1) HUE054724T2 (es)
IL (2) IL255430B (es)
JO (2) JOP20160086B1 (es)
LT (1) LT3294738T (es)
MD (1) MD3294738T2 (es)
MX (2) MX391754B (es)
MY (1) MY198339A (es)
NI (1) NI201700137A (es)
PE (2) PE20180232A1 (es)
PH (1) PH12017502000B1 (es)
PL (1) PL3294738T3 (es)
RS (1) RS62029B1 (es)
SG (1) SG10201900315SA (es)
SI (1) SI3294738T1 (es)
SM (1) SMT202100367T1 (es)
SV (1) SV2017005557A (es)
TW (2) TWI744963B (es)
UA (2) UA128183C2 (es)
UY (2) UY39706A (es)
WO (1) WO2016180696A1 (es)
ZA (2) ZA201707524B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
PT3201177T (pt) * 2014-10-01 2019-02-12 Univ Leuven Kath Indóis mono- ou di-substituídos como inibidores de replicação viral do dengue
TWI681951B (zh) * 2014-10-01 2020-01-11 美商健生醫藥公司 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436435B1 (en) 2016-03-31 2021-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
SG11201808237UA (en) * 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) * 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
PE20200604A1 (es) * 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
US20220409583A1 (en) * 2019-11-15 2022-12-29 Janssen Pharmaceuticals, Inc. Treatment and Prevention of Dengue Disease
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团(天津)股份有限公司 连续化合成取代吲哚-2-羧酸的方法
BR112023027328A2 (pt) 2021-06-29 2024-03-12 Janssen Pharmaceuticals Inc Processos para a preparação de derivados de (s)-2-(4-cloro-2-metoxifenil)-2-((3-metóxi-5-(metilsulfonil)fenil)amino)-1-(1h-indol-3-il)etenona
WO2023218285A1 (en) 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
WO2026018176A1 (en) 2024-07-17 2026-01-22 Janssen Pharmaceuticals, Inc. 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021559A1 (en) 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
JP2008526980A (ja) 2005-01-14 2008-07-24 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染症を治療するためのインドール誘導体
MX2007009561A (es) 2005-02-09 2008-01-14 Migenix Inc Composiciones y metodos para tratar o evitar infecciones de flaviviridae.
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
CA2733554A1 (en) * 2008-08-18 2010-02-25 Yale University Mif modulators
ES2612731T3 (es) * 2008-08-19 2017-05-18 Janssen Pharmaceutica Nv Antagonistas de receptores al frío de mentol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
NZ600816A (en) 2010-01-15 2014-08-29 Gilead Sciences Inc Inhibitors of flaviviridae viruses
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用
BR112016015717B1 (pt) 2014-01-31 2023-04-04 Bristol-Myers Squibb Company Compostos macrociclos com grupos p2' heterocíclicos como inibidores do fator xia, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos
IL319240A (en) 2014-06-04 2025-04-01 Amgen Inc Methods for collecting mammalian cell cultures
AU2015271689C1 (en) 2014-06-04 2019-01-17 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using Notch 1 and/or Notch 2 agonists
TWI681951B (zh) 2014-10-01 2020-01-11 美商健生醫藥公司 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物
PT3201177T (pt) * 2014-10-01 2019-02-12 Univ Leuven Kath Indóis mono- ou di-substituídos como inibidores de replicação viral do dengue
NO2721243T3 (es) 2014-10-01 2018-10-20
LT3204517T (lt) 2014-10-10 2021-11-25 Rutgers, The State University Of New Jersey Polimerazės grandininės reakcijos pradmenys ir zondai, skirti mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016296923B2 (en) 2015-07-22 2019-02-21 Board Of Regents, The University Of Texas System Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016350868B2 (en) 2015-11-03 2022-03-31 Zoetis Services Llc Sol-gel polymer composites and uses thereof
EP3436435B1 (en) 2016-03-31 2021-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
TWI691596B (zh) 2016-04-01 2020-04-21 美商凱特製藥公司 嵌合抗原和t細胞受體及使用方法
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
PE20181898A1 (es) 2016-04-01 2018-12-11 Basf Se Compuestos biciclicos
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
NZ746554A (en) 2016-04-01 2023-03-31 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
PE20200400A1 (es) 2016-04-01 2020-02-26 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
GB2573909B (en) 2017-03-17 2020-05-20 Mitsubishi Electric Corp Adaptive array antenna device
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
PE20200604A1 (es) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Also Published As

Publication number Publication date
GT201700234A (es) 2018-11-26
EP3896072A1 (en) 2021-10-20
UA128183C2 (uk) 2024-05-01
ZA201707524B (en) 2024-06-26
JP2022166289A (ja) 2022-11-01
EP3294738A1 (en) 2018-03-21
HRP20210675T1 (hr) 2021-06-25
AU2020273314A1 (en) 2020-12-17
TWI725969B (zh) 2021-05-01
US20180346419A1 (en) 2018-12-06
EA034978B1 (ru) 2020-04-14
JP2018515495A (ja) 2018-06-14
ES2941674T3 (es) 2023-05-24
PE20180232A1 (es) 2018-01-31
SI3294738T1 (sl) 2021-08-31
IL272814A (en) 2020-04-30
CO2017012381A2 (es) 2018-03-28
JP7132399B2 (ja) 2022-09-06
DK3294738T3 (da) 2021-06-28
MD3294738T2 (ro) 2021-08-31
ZA202002435B (en) 2023-03-29
US10696632B2 (en) 2020-06-30
SG10201900315SA (en) 2019-02-27
CR20200152A (es) 2020-09-08
JP6898493B2 (ja) 2021-07-07
TW202041499A (zh) 2020-11-16
AU2016259677A1 (en) 2017-10-26
UA121332C2 (uk) 2020-05-12
PH12017502000A1 (en) 2018-03-26
LT3294738T (lt) 2021-08-25
US11827602B2 (en) 2023-11-28
JP6752821B2 (ja) 2020-09-09
JP2020125316A (ja) 2020-08-20
IL255430A0 (en) 2017-12-31
IL272814B (en) 2021-02-28
NZ765879A (en) 2024-09-27
TW201704208A (zh) 2017-02-01
KR102610491B1 (ko) 2023-12-06
PH12017502000B1 (en) 2018-03-26
MY198339A (en) 2023-08-27
CY1124548T1 (el) 2022-07-22
CA2981845A1 (en) 2016-11-17
CN113045476A (zh) 2021-06-29
CN113045476B (zh) 2024-07-16
KR20210048578A (ko) 2021-05-03
CN107873022A (zh) 2018-04-03
TWI744963B (zh) 2021-11-01
CN111303000B (zh) 2023-11-28
NZ736934A (en) 2023-11-24
PL3294738T3 (pl) 2021-12-13
JP7451626B2 (ja) 2024-03-18
BR112017023904A2 (pt) 2018-07-17
HK1252446A1 (zh) 2019-05-24
CN107873022B (zh) 2021-03-12
JP2021138752A (ja) 2021-09-16
US20240182414A1 (en) 2024-06-06
WO2016180696A1 (en) 2016-11-17
SMT202100367T1 (it) 2021-07-12
UY39706A (es) 2022-05-31
KR102610493B1 (ko) 2023-12-05
US10919854B2 (en) 2021-02-16
SV2017005557A (es) 2018-06-26
IL255430B (en) 2020-03-31
ECSP17073878A (es) 2018-02-28
AU2016259677B2 (en) 2020-10-01
MX383932B (es) 2025-03-14
US20250230127A1 (en) 2025-07-17
AU2020273314B2 (en) 2021-10-21
US12172959B2 (en) 2024-12-24
RS62029B1 (sr) 2021-07-30
UY36674A (es) 2016-11-30
MX2017014293A (es) 2018-08-09
CL2017002817A1 (es) 2018-05-11
MX2020011156A (es) 2022-04-21
CN111303000A (zh) 2020-06-19
HUE054724T2 (hu) 2021-09-28
MX391754B (es) 2025-03-21
US20210171462A1 (en) 2021-06-10
HK1252496A1 (zh) 2019-05-31
EP3896072B1 (en) 2022-11-16
CR20170490A (es) 2018-03-08
KR20180002644A (ko) 2018-01-08
CA2981845C (en) 2022-03-08
EP3294738B1 (en) 2021-04-07
ECSP22023220A (es) 2022-05-31
PE20221579A1 (es) 2022-10-06
EA201792429A1 (ru) 2018-02-28
ES2877404T3 (es) 2021-11-16
JOP20210109A1 (ar) 2023-01-30
JOP20160086B1 (ar) 2021-08-17
US20200270209A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue